Kiora (KPRX) Director David Hollander Receives 25,000-Share Option

What Happened
David Hollander, a director of Kiora Pharmaceuticals, was granted a derivative award on 2026-06-10: an option to purchase 25,000 shares of common stock. The filing reports an acquisition at $0.00 per share (total reported value $0). The option will become fully exercisable on June 10, 2027. No shares were sold and no cash was exchanged at grant.

Key Details

• Transaction date: 2026-06-10; Form 4 filed: 2026-06-12 (timely, within the usual two-business-day window).
• Transaction type/code: Award/Grant (A), derivative security (option).
• Amount: option covering 25,000 shares; exercise price reported as $0.00; reported value $0.
• Vesting/exercise: Option becomes fully exercisable on June 10, 2027 (per footnote F1).
• Shares owned after transaction: Not disclosed in the provided filing.
• Footnote: F1 states the option was granted under the Issuer’s 2024 Equity Incentive Plan and will be fully exercisable on 2027-06-10.
• No immediate sale or cashless exercise reported.

Context
This is a compensation/retention-style option grant (a derivative award). Until Hollander exercises the option, he does not hold the underlying common shares and there is no immediate change in his reported common-stock ownership or company cash. Such grants are common for directors and aim to align long-term interests with shareholders; they are informational rather than direct market trades.